Sai Life Sciences Q2 FY27: Rev ₹553 Cr

Metric	Value
Revenue	₹553 Cr

📢 Key Event
Sai Life Sciences reported 12% YoY revenue growth to INR 553 crores in Q1 FY27, driven by CRO and CDMO expansion.

🔄 What Changed
Revenue reached INR 553 crores with 12% YoY growth; EBITDA guidance maintained at 28-30%; capex range set at INR 1,100-1,300 crores for FY27; six Phase 3 molecules in pipeline.

🔮 What's Next
15% to 20% revenue growth and 28% to 30% EBITDA margin guidance for FY27; two new large pharma FTE contracts planned by Q2; peptide facility operational by 2028; updates on AI initiatives expected by year-end.

💡 Investor Takeaway
The company is scaling capacity and services to capture higher-value integrated partnerships, with growth anchored in repeat business and pipeline depth, though near-term revenue guidance remains conservative.

Sai Life Sciences reported a 12% YoY revenue increase to INR 553 crores in Q1 FY27, driven by 26% growth in CRO and 6% in CDMO, supported by strong repeat business exceeding 90% of revenue and strategic expansion into peptides, ADCs, and PROTACs. Management highlighted ongoing capex of INR 1,100-1,300 crores for FY27, including a greenfield peptide facility targeting 2028 readiness, and maintained 15-20% revenue growth and 28-30% EBITDA guidance. The company emphasized deepening client relationships through integrated services, with six Phase 3 molecules in pipeline and two FY26 regulatory approvals, while advancing AI initiatives to enhance R&D efficiency and modular capacity scaling aligned with demand.

📄 View Original Announcement (PDF)

📊 Stock Analysis — SAILIFE ✨ Ask AI About This

About Sai Life Sciences Limited (SAILIFE)

Healthcare · Pharmaceuticals · Listed on NSE

Market Cap: ₹30,970.41 Cr P/E: 85.0 ROE: 14.6% ROCE: 20.1%

View full SAILIFE stock details →

📡 Get AI alerts when SAILIFE files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track SAILIFE — Free

💡 Ask AI about this filing

"What is the expected revenue contribution from the new peptide facility after 2028?" "How will AI initiatives impact operating margins in the next fiscal year?" "When will the first FY26 regulatory approval translate into commercial revenue?"

Ask AI Free →

📊 More SAILIFE filings

See all SAILIFE filings →

🔥 Also filed on 12 August 2026

DBL Dilip Buildcon Limited Corporate Action NITCO Nitco Limited Financial Results KPIGREEN KPI Green Energy Limited Financial Results SDBL Som Distilleries & Breweries Limited Financial Results CONSOFINVT Consolidated Finvest & Holdings Limited Corporate Action TOUCHWOOD Touchwood Entertainment Limited Financial Results

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when SAILIFE files new disclosures

Track SAILIFE filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track SAILIFE — Free

Free account · 2 AI queries/day

About · Privacy Policy · Terms of Service · Pricing

Today's Announcements · Screener · Insights · AI Chat

Data provided by CMOTS Internet Technologies Pvt Ltd